NLS Pharmaceutics Merger Registration Statement Effective
Ticker: NCEL · Form: 6-K · Filed: Sep 10, 2025 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Sep 10, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: merger, registration-statement, sec-filing
Related Tickers: NLS
TL;DR
NLS Pharma & Kadimastem merger SEC filing is now effective. Deal moving forward.
AI Summary
On September 10, 2025, NLS Pharmaceutics Ltd. announced that the SEC registration statement related to its proposed merger with Kadimastem has become effective. This filing, designated as Report No. 2 for September 2025, is a Form 6-K, indicating it's a report from a foreign private issuer.
Why It Matters
The effectiveness of the SEC registration statement is a crucial step towards the completion of the proposed merger between NLS Pharmaceutics and Kadimastem, potentially impacting the combined entity's future operations and market position.
Risk Assessment
Risk Level: medium — Merger effectiveness is positive, but the success of the merger itself and its impact on the company's value are still subject to various risks.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- Kadimastem (company) — Party to proposed merger
- September 10, 2025 (date) — Date of press release and filing
- SEC (company) — Regulatory body
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K filing reports that the SEC registration statement in connection with the proposed merger between NLS Pharmaceutics Ltd. and Kadimastem has become effective.
Who are the main companies involved in the announcement?
The main companies involved are NLS Pharmaceutics Ltd. and Kadimastem.
When was the press release announcing the effectiveness of the registration statement issued?
The press release was issued on September 10, 2025.
What is the filing number for NLS Pharmaceutics Ltd. with the SEC?
The commission file number for NLS Pharmaceutics Ltd. is 001-39957.
What type of document is being furnished as Exhibit 99.1?
Exhibit 99.1 is a press release titled 'Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger.'
Filing Stats: 209 words · 1 min read · ~1 pages · Grade level 11.7 · Accepted 2025-09-10 06:15:33
Filing Documents
- ea0256720-6k_nlspharma.htm (6-K) — 10KB
- ea025672001ex99-1_nlspharma.htm (EX-99.1) — 19KB
- ex99-1_001.jpg (GRAPHIC) — 76KB
- 0001213900-25-086348.txt ( ) — 135KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: September 10, 2025 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 3